Comprehensive analysis of glycometabolism-related genes reveals PLOD2 as a prognostic biomarker and therapeutic target in gastric cancer
Abstract Background Gastric cancer (GC) is one of the leading causes of cancer-related mortality worldwide, with limited therapeutic options and a poor prognosis, particularly in advanced stages. Glycometabolism, a hallmark of cancer, plays a critical role in tumor progression, immune evasion, and r...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-04-01
|
| Series: | BMC Gastroenterology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12876-025-03878-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850181905693016064 |
|---|---|
| author | Wanchun Ye Xiaolei Zhang Zhongjie Tang Yufeng Hu Yuanliang Zheng Yuping Yuan |
| author_facet | Wanchun Ye Xiaolei Zhang Zhongjie Tang Yufeng Hu Yuanliang Zheng Yuping Yuan |
| author_sort | Wanchun Ye |
| collection | DOAJ |
| description | Abstract Background Gastric cancer (GC) is one of the leading causes of cancer-related mortality worldwide, with limited therapeutic options and a poor prognosis, particularly in advanced stages. Glycometabolism, a hallmark of cancer, plays a critical role in tumor progression, immune evasion, and response to therapy. However, the specific roles of glycometabolism-related genes and their prognostic and therapeutic implications in GC remain inadequately understood. Methods Transcriptomic and clinical data from GC patients were retrieved from TCGA and GEO databases. Glycometabolism-related genes were identified and analyzed using machine learning algorithms to construct a prognostic model. Functional assays, immune profiling, and pathway enrichment analyses were performed to explore the roles of these genes in tumor progression, immune-modulatory effects, and drug resistance. PLOD2, the gene with the highest prognostic significance, was further investigated to uncover its underlying regulatory mechanisms, roles in immune modulation, and contribution to therapeutic resistance. Results A glycometabolism-related prognostic model consisting of four genes (PLOD2, CHSY3, SLC2A3 and SLC5A1) was developed and validated, effectively stratifying GC patients into high- and low-risk subgroups with distinct survival outcomes. Among these, PLOD2 emerged as the most significant gene, exhibiting strong associations with tumor progression and poor survival. Functional analyses revealed that PLOD2 promotes glycolysis and tumor progression through activation of the PI3K/AKT/mTOR pathway. Immune profiling revealed that PLOD2 overexpression is associated with an immunosuppressive tumor microenvironment, characterized by increased M2 macrophage infiltration and reduced immune activity. Moreover, treatment with rapamycin, an mTOR inhibitor, significantly suppressed PLOD2-mediated proliferation and anchorage-independent growth in GC cells, highlighting the central role of the PI3K/AKT/mTOR pathway in PLOD2-driven oncogenic behaviors. Conclusions This study identifies PLOD2 as a key prognostic biomarker and therapeutic target in gastric cancer. As a central component in a glycometabolism-related model, PLOD2 promotes glycolysis, tumor progression, and immune evasion via the PI3K/AKT/mTOR pathway. The model effectively stratifies patient risk, offering both prognostic utility and therapeutic insight. Targeting PLOD2-mediated pathways may represent a promising strategy for precision therapy and improved clinical outcomes in gastric cancer. |
| format | Article |
| id | doaj-art-9323bd3db01e44f4a9240c4490f05f22 |
| institution | OA Journals |
| issn | 1471-230X |
| language | English |
| publishDate | 2025-04-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Gastroenterology |
| spelling | doaj-art-9323bd3db01e44f4a9240c4490f05f222025-08-20T02:17:47ZengBMCBMC Gastroenterology1471-230X2025-04-0125111710.1186/s12876-025-03878-zComprehensive analysis of glycometabolism-related genes reveals PLOD2 as a prognostic biomarker and therapeutic target in gastric cancerWanchun Ye0Xiaolei Zhang1Zhongjie Tang2Yufeng Hu3Yuanliang Zheng4Yuping Yuan5The Dingli Clinical College of Wenzhou Medical University, Wenzhou Central Hospital, The Second Affiliated Hospital of Shanghai UniversityDepartment of Clinical Laboratory, Jinan Fourth People’s HospitalThe Dingli Clinical College of Wenzhou Medical University, Wenzhou Central Hospital, The Second Affiliated Hospital of Shanghai UniversityThe Dingli Clinical College of Wenzhou Medical University, Wenzhou Central Hospital, The Second Affiliated Hospital of Shanghai UniversityThe Dingli Clinical College of Wenzhou Medical University, Wenzhou Central Hospital, The Second Affiliated Hospital of Shanghai UniversityThe Dingli Clinical College of Wenzhou Medical University, Wenzhou Central Hospital, The Second Affiliated Hospital of Shanghai UniversityAbstract Background Gastric cancer (GC) is one of the leading causes of cancer-related mortality worldwide, with limited therapeutic options and a poor prognosis, particularly in advanced stages. Glycometabolism, a hallmark of cancer, plays a critical role in tumor progression, immune evasion, and response to therapy. However, the specific roles of glycometabolism-related genes and their prognostic and therapeutic implications in GC remain inadequately understood. Methods Transcriptomic and clinical data from GC patients were retrieved from TCGA and GEO databases. Glycometabolism-related genes were identified and analyzed using machine learning algorithms to construct a prognostic model. Functional assays, immune profiling, and pathway enrichment analyses were performed to explore the roles of these genes in tumor progression, immune-modulatory effects, and drug resistance. PLOD2, the gene with the highest prognostic significance, was further investigated to uncover its underlying regulatory mechanisms, roles in immune modulation, and contribution to therapeutic resistance. Results A glycometabolism-related prognostic model consisting of four genes (PLOD2, CHSY3, SLC2A3 and SLC5A1) was developed and validated, effectively stratifying GC patients into high- and low-risk subgroups with distinct survival outcomes. Among these, PLOD2 emerged as the most significant gene, exhibiting strong associations with tumor progression and poor survival. Functional analyses revealed that PLOD2 promotes glycolysis and tumor progression through activation of the PI3K/AKT/mTOR pathway. Immune profiling revealed that PLOD2 overexpression is associated with an immunosuppressive tumor microenvironment, characterized by increased M2 macrophage infiltration and reduced immune activity. Moreover, treatment with rapamycin, an mTOR inhibitor, significantly suppressed PLOD2-mediated proliferation and anchorage-independent growth in GC cells, highlighting the central role of the PI3K/AKT/mTOR pathway in PLOD2-driven oncogenic behaviors. Conclusions This study identifies PLOD2 as a key prognostic biomarker and therapeutic target in gastric cancer. As a central component in a glycometabolism-related model, PLOD2 promotes glycolysis, tumor progression, and immune evasion via the PI3K/AKT/mTOR pathway. The model effectively stratifies patient risk, offering both prognostic utility and therapeutic insight. Targeting PLOD2-mediated pathways may represent a promising strategy for precision therapy and improved clinical outcomes in gastric cancer.https://doi.org/10.1186/s12876-025-03878-zGastric cancerGlycometabolismPLOD2Immune evasionPI3K/AKT/mTOR pathwayPrognostic model |
| spellingShingle | Wanchun Ye Xiaolei Zhang Zhongjie Tang Yufeng Hu Yuanliang Zheng Yuping Yuan Comprehensive analysis of glycometabolism-related genes reveals PLOD2 as a prognostic biomarker and therapeutic target in gastric cancer BMC Gastroenterology Gastric cancer Glycometabolism PLOD2 Immune evasion PI3K/AKT/mTOR pathway Prognostic model |
| title | Comprehensive analysis of glycometabolism-related genes reveals PLOD2 as a prognostic biomarker and therapeutic target in gastric cancer |
| title_full | Comprehensive analysis of glycometabolism-related genes reveals PLOD2 as a prognostic biomarker and therapeutic target in gastric cancer |
| title_fullStr | Comprehensive analysis of glycometabolism-related genes reveals PLOD2 as a prognostic biomarker and therapeutic target in gastric cancer |
| title_full_unstemmed | Comprehensive analysis of glycometabolism-related genes reveals PLOD2 as a prognostic biomarker and therapeutic target in gastric cancer |
| title_short | Comprehensive analysis of glycometabolism-related genes reveals PLOD2 as a prognostic biomarker and therapeutic target in gastric cancer |
| title_sort | comprehensive analysis of glycometabolism related genes reveals plod2 as a prognostic biomarker and therapeutic target in gastric cancer |
| topic | Gastric cancer Glycometabolism PLOD2 Immune evasion PI3K/AKT/mTOR pathway Prognostic model |
| url | https://doi.org/10.1186/s12876-025-03878-z |
| work_keys_str_mv | AT wanchunye comprehensiveanalysisofglycometabolismrelatedgenesrevealsplod2asaprognosticbiomarkerandtherapeutictargetingastriccancer AT xiaoleizhang comprehensiveanalysisofglycometabolismrelatedgenesrevealsplod2asaprognosticbiomarkerandtherapeutictargetingastriccancer AT zhongjietang comprehensiveanalysisofglycometabolismrelatedgenesrevealsplod2asaprognosticbiomarkerandtherapeutictargetingastriccancer AT yufenghu comprehensiveanalysisofglycometabolismrelatedgenesrevealsplod2asaprognosticbiomarkerandtherapeutictargetingastriccancer AT yuanliangzheng comprehensiveanalysisofglycometabolismrelatedgenesrevealsplod2asaprognosticbiomarkerandtherapeutictargetingastriccancer AT yupingyuan comprehensiveanalysisofglycometabolismrelatedgenesrevealsplod2asaprognosticbiomarkerandtherapeutictargetingastriccancer |